In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Behnaz GhaemiRussell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2220-0428 Hernando Lopez-BertoniDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6618-1092 Shreyas KuddannayaRussell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-9248-1355 Sophie SallDepartment of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0009-0001-4234-4077 John LaterraDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Guanshu LiuRussell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-8188-4332 Jeff W M BulteRussell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-1202-1610 Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6MTraining/Dissemination-Resource for Molecular Imaging Agents in Precision MedicineP41EB024495 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MARTIN G POMPER · 2017 to 2026
$11.8MSleep and Circadian Dysfunction, Brain and Neurobehavioral Development in AutismP50HD103538 · NICHD · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI Stewart H Mostofsky · 2020 to 2026
$9.9MChromatin Modifications in GBM-Propagating CellsR01NS096754 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LATERRA, JOHN J · 2017 to 2021
$2.2MIntracellular Self-Assembly of Theranostic Nanoparticles for Enhanced Imaging and Tumor TherapyR01EB030376 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI BULTE, JEFF W. · 2020 to 2024
$2.1MMolecular determinants of cellular heterogeneity and therapeutic resistance in GBM.R01NS120949 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LOPEZ-BERTONI, HERNANDO MARTIN · 2021 to 2025
$2.0MMultimodal MRI for guiding bacterial cancer therapyR01CA261974 · NCI · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI Renyuan Bai, Guanshu Liu · 2022 to 2026
$1.8MBrain Cancer Stem Cell Reprogramming by c-MetR01NS073611 · NINDS · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI LATERRA, JOHN J · 2012 to 2016
$1.8MUpgrade of the 11.7T Research Scanner at the F.M. Kirby Research CenterS10OD032188 · OD · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI VAN ZIJL, PETER CM · 2024 to 2024
$1.7MNCI NIH HHS P30 CA006973NCI NIH HHS R01 CA261974NIBIB NIH HHS P41 EB024495NIBIB NIH HHS R01 EB030376NICHD NIH HHS P50 HD103538NIH HHS S10 OD032188NINDS NIH HHS R01 NS073611NINDS NIH HHS R01 NS096754NINDS NIH HHS R01 NS120949
6 · The paper itselfAbstract
Glioblastoma (GBM) contains mesenchymal cancer stem cells that drive tumor aggressiveness and recurrence and exhibit aberrant glycosylation during proneural-to-mesenchymal transition. A comprehensive computational analysis of human GBM transcriptomic datasets revealed an up-regulation of 13 genes involved in glycan mannosylation compared to normal brain, and histopathological staining of a tissue array representing 35 GBM cases revealed elevated mannose levels that correlated with increased expression of the mesenchymal marker CD44. Hydroxyl proton transfer-weighted magnetic resonance imaging (HPTw MRI) detected elevated mannose levels in aggressive human mesenchymal GBM in vitro and in vivo but not in GBM with a less aggressive nonmesenchymal phenotype. To establish causation over correlation, inhibiting expression of the mannose-binding lectins LMAN1/2 that regulate intracellular processing of mannosylated proteins decreased the glioma cell HPTw MRI signal. Our findings indicate that HPTw MRI correlates with high mannose and possibly other saccharide levels in mesenchymal GBM cells, serving as a surrogate imaging biomarker for predicting tumor aggressiveness and recurrence.
Indexed as
Biomarkers, TumorBrain NeoplasmsGlioblastomaMagnetic Resonance ImagingMannoseAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsMesenchymal Stem CellsProtonsBiomarkers, TumorHyaluronan ReceptorsMannoseProtons
Identifiers
PMID42127174
PMCPMC13170648
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390